Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

Late-stage candidate hit the mark in phase 3 study

- PMLiVE

New faces at JPA Health Communications, GCI Health and HRW

The latest movers in healthcare comms

- PMLiVE

Correvio crumbles as FDA panel rejects AFib drug

Panel voted 11 to two against approval of drug

- PMLiVE

Regeneron reveals first data for bispecific antibody in multiple myeloma

Could be a pivotal treatment for patients who have exhausted options

- PMLiVE

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Acquisition bolsters immuno-oncology pipeline

- PMLiVE

Merck buys ArQule for $2.7bn in another cancer bolt-on deal

Deal due to close in the first quarter of 2020

- PMLiVE

J&J splashes $750m on anti-inflammatory drug bermekimab

The drug is currently in phase 2 clinical development

- PMLiVE

J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data

Both candidates are being studied in multiple myeloma

- PMLiVE

Healthcare trends 2020 – the biggest shifts changing lives and life sciences

By Julie Adrian

- PMLiVE

AstraZeneca’s Calquence impresses in previously untreated CLL

Takes the fight to AbbVie/J&J’s Imbruvica

- PMLiVE

Bluebird bio’s sickle cell gene therapy shows early-study benefit

Closely follows approval of beta thalassaemia therapy Zynteglo

Bristol Myers Squibb logo

Armed with new data, BMS plans filings for Celgene CAR-T liso-cel

Achieved a 53% complete response rate in study participants

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links